All‐cause mortality · adults with CVCs
It is very uncertain whether heparin changes mortality compared with normal saline solution locking (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with non‐ST elevation acute coronary syndromes
Heparin showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Neonatal mortality · preterm infants at risk of intraventricular haemorrhage
Heparin showed no clear difference in neonatal mortality (all‐cause) compared with placebo/no treatment (low certainty).
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
VTE‐related mortality4 · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality · patients with cancer with venous thromboembolism
Low molecular weight heparin showed no clear difference in mortality compared with unfractionated heparin (low certainty).
1 finding from 1 review
All cause mortality (timing not specified) · people undergoing major amputation of the lower extremity
1 finding from 1 review
All‐cause mortality · people undergoing bariatric surgery
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with low molecular weight heparin (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in VTE‐related mortality at 3 months compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
VTE‐related mortality4 · people undergoing bariatric surgery
1 finding from 1 review
All‐cause mortality (7 days ‐ 3 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (7 days ‐ 3 months) compared with low molecular weight heparin (low certainty).
1 finding from 1 review
All‐cause mortality (5 days to 12 months) · people aged ≥ 18 years with a diagnosis of new or recurrent VTE
Subcutaneous unfractionated heparin showed no clear difference in all‐cause mortality (5 days to 12 months) compared with intravenous unfractionated heparin (low certainty).
1 finding from 1 review
All cause mortality · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality
Heparin prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).
2 findings from 1 review
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Heparin changes mortality attributable to hepatic veno‐occlusive disease ( compared with low molecular weight heparin (very low certainty).
1 finding from 1 review
Mortality due to other causes · prevention of venous thromboembolism in patients with lower‐limb immobilization
Low molecular weight heparin showed no clear difference in mortality due to other causes compared with no prophylaxis or placebo (low certainty).
1 finding from 1 review
Mortality due to pulmonary embolism · prevention of venous thromboembolism in patients with lower‐limb immobilization
1 finding from 1 review
All‐cause mortality(7‐day) · people with intermediate‐risk (submassive) APE
1 finding from 1 review